Clinical Trials Directory

Trials / Unknown

UnknownNCT04792658

Impact of Long Term of Benzodiazepine Use on Psychiatric Manifestation

Impact of Long Term of Benzodiazepine Use on Psychiatric Manifestation in Neuropsychiatric Disease

Status
Unknown
Phase
Study type
Observational
Enrollment
100 (estimated)
Sponsor
Assiut University · Academic / Other
Sex
All
Age
18 Years – 50 Years
Healthy volunteers
Accepted

Summary

Benzodiazepines are usually a secondary drug of abuse-used mainly to augment the high received from another drug or to offset the adverse effects of other drugs. Few cases of addiction arise from legitimate use of benzodiazepines. Pharmacologic dependence, a predictable and natural adaptation of a body system long accustomed to the presence of a drug, may occur in patients taking therapeutic doses of benzodiazepines. However, this dependence, which generally manifests itself in withdrawal symptoms upon the abrupt discontinuation of the medication, may be controlled and ended through dose tapering, medication switching, and/or medication augmentation. Due to the chronic nature of anxiety, long-term low-dose benzodiazepine treatment may be necessary for some patients; this continuation of treatment should not be considered abuse or addiction. previous study reported that The results of the study are important in that they corroborate the mounting evidence that a range of neuropsychological functions are impaired as a result of long-term benzodiazepine use, and that these are likely to persist even following withdrawal. The findings highlight the residual neurocognitive compromise associated with long-term benzodiazepine therapy as well as the important clinical implications of these results.

Conditions

Interventions

TypeNameDescription
BEHAVIORALDetailed interview with personal demographic data, such as age, sex, education, history of occupation, past medical history, family history, medical, neurological, and psychiatric disorders.
BEHAVIORALIntelligence assessment using the Arabic version of the Wechsler Adult Intelligence Scale (WAIS)the test consists of six verbal subtests and five performance subtests. It used in measure Intelligence
BEHAVIORALThe Arabic version of the Structured Interview for the Five-Factor Personality Model (SIFFM)it depend on a model of general language personality descriptors that based on theory suggests five broad dimensions to describe human personality
BEHAVIORALthe Hamilton Depression Rating Scaleit used for evaluation depression severity. It is 17 items and each item's score (0-4). with a total score range of 0-54
BEHAVIORALThe Hamilton Anxiety Rating Scaleit used for evaluation the severity of anxiety. The scale consists of 14 items and each item is scored on a scale from 0 to 4 , with a total score range of 0-56
BEHAVIORALThe Minnesota Multiphasic Personality Inventory-2 (MMPI-2)It used to evaluate range of symptoms of psychopathology and personality traits that are maladaptive. It has 10 clinical scales subscales included the following: 1, hypochondriasis (Hs); 2, depression (D); 3, hysteria (Hy); 4, psychopathic deviation (Pd); 5, masculinity-femininity (Mf); 6, paranoia (Pa); 7, psychophrenia (Pt); 8, schizophrenia (Sc); 9, hypomania (Ma); 10, social introversion (Ma); (Si). More than 65 responses were considered symptomatic

Timeline

Start date
2021-03-10
Primary completion
2022-06-20
Completion
2023-09-20
First posted
2021-03-11
Last updated
2021-03-11

Source: ClinicalTrials.gov record NCT04792658. Inclusion in this directory is not an endorsement.